The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

Brookline Capital Markets analysts initiated coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and a $40 price target, ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer.

Another notable valuation metric for EXEL is its P/B ratio of 4.24. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total ...

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.48 which represents a slight increase of $0.19 or 0.57% from the prior close of $33.29. The stock opened at $33.46 and touched a ...

Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...

Brookline Capital Markets analysts initiated coverage of Exelixis (NASDAQ:EXEL) with a Buy rating, highlighting the biotech ...